SAN DIEGO , March 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon") (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the appointment of Angela Rossetti to the Aethlon Board of Directors, effective April 1, 2022 . Ms. Rossetti replaces Sabrina Martucci Johnson , who has served on the Aethlon Board of Directors since 2018 and is stepping down on April 1, 2022 to focus on her other roles.
"We sincerely thank Sabrina Martucci Johnson for her valuable contributions to the Company and her years of service on the Aethlon Board. Sabrina has been a highly valued member of the Board and provided exceptional guidance to Aethlon during her years of service," said Charles J. Fisher Jr. , MD, CEO of Aethlon.
"It is with great pleasure that we welcome Angela to Aethlon. Angela brings extensive commercial and operational expertise, gained from her experience in several top positions within leading biopharmaceutical companies," said Dr. Fisher. "We believe her involvement across medical, clinical and regulatory affairs will be an invaluable asset to Aethlon, and we look forward to leveraging her wealth of knowledge to assist with the clinical advancement of our Hemopurifier®, as a treatment for infectious diseases and cancer."
Ms. Rossetti is a senior biopharmaceutical executive who brings more than 20 years of industry experience. She has served as a strategic consultant to Kala Pharmaceuticals, Inc. since October 2021 , and prior to this was a consultant to Celgene Corporation. From June 2015 through July 2017 , Ms. Rossetti held the position of Executive Vice President of Cell Machines, Inc., an early-stage biopharmaceutical company developing novel protein therapies where she assisted with the commercialization of technology for hemophilia and other diseases. Ms. Rossetti has held a number of positions within pharmaceutical commercial development, marketing, communications and finance, including Vice President of a Global Commercial Medicine Team at Pfizer Inc., where she led a global smoking cessation campaign. Ms. Rossetti currently holds positions as an adjunct Assistant Professor of Medical and Pharmaceutical Ethics at New York Medical College and an Adjunct Associate at Albert Einstein College of Medicine.
Ms. Rossetti graduated from a joint program between Albert Einstein College of Medicine and Benjamin N. Cardozo School of Law with an M.S. in Bioethics. She received an M.B.A. from Columbia University Graduate School of Business and a B.A. in Biology and English from the University of Pennsylvania .
About Aethlon and the Hemopurifier®
Aethlon Medical, Inc. is a biotechnology company developing the Hemopurifier, a therapeutic blood purifier indicated for infectious diseases and cancer. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. A recent amendment to the IDE enabled Aethlon to implement a new EFS protocol to treat up to 40 COVID-19 patients at up to 20 clinical sites in the U.S. In two case studies of patients treated under Emergency Use (EU), the Hemopurifier demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus from the circulation of a human patient.
Additional information can be found at www.AethlonMedical.com.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to enroll additional sites for its clinical trials, the Company's ability to enroll patients in and successfully complete its trials in COVID-19 patients and in its head and neck cancer trials, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2021 , and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact: Jim Frakes Chief Financial Officer Aethlon Medical, Inc. Jfrakes@aethlonmedical.com
Media Contact: Tony Russo , Ph.D. Russo Partners, LLC tony.russo@russopartnersllc.com 212-845-4251
Investor Contact: Susan Noonan S.A. Noonan Communications, LLC susan@sanoonan.com 212-966-3650
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-inc-appoints-angela-rossetti-to-board-of-directors-301511224.html
An important U.S. regulator raises concerns about 'fraudulent and manipulative acts and practices.'
Yahoo Finance's Anjalee Khemlani details Dr. Anthony Fauci's addressing the latest COVID-19 strain, the Omicron BA.2 subvariant, changing health guidelines, and progress in the latest vaccines getting FDA approval.
Shares of Clovis Oncology (NASDAQ: CLVS) jumped 80% this week, according to data from S&P Global Market Intelligence. Clovis' big move didn't come until Thursday, however, when the company announced positive data regarding its drug Rubraca (rucaparib). It was a big development for the company as its shares had fallen significantly from last year, when it was trading as high as $11 a share early in February.
Betting on turnarounds in companies that others are too scared to touch can be a successful strategy for some investors. Farsighted investors who recognize the enduring potential of a business -- even during its most vulnerable hours -- can sometimes (but of course, not always) get outsize returns if they're right. One biotech stock that could be ripe for exactly that kind of play is Cassava Sciences (NASDAQ: SAVA), which is down over 70% from its high in July of last year as a result of a parade of misfortunes.
Shares of Qualcomm (NASDAQ: QCOM) were trading about 6% lower at 2 p.m. ET Friday after a JPMorgan analyst removed the semiconductor giant from its "analyst focus list," indicating that the firm no longer sees it as a top stock with meaningful upside from its current price.
What happened Shares of semiconductor giant Nvidia (NASDAQ: NVDA) dropped in Friday afternoon trading, falling 2.9% through 12:55 p.m. ET. In the absence of any other news on Nvidia stock per se, it appears today's drop is tied to a Yahoo! Finance column that may have spooked investors.
DEEP DIVE It sure has been a wild ride for investors over the past few weeks, with the benchmark S&P 500 rising 10% from March 8 through March 30. But the broader stock market is still down for 2022.
Measuring and gauging the stock market's value is key to an investor’s strategy. Right now, it’s clear that the market is in the midst of a shift, that last year’s sustained run of gains has ended, that this year, which started with sharp losses and increased volatility, will be something different. Covering the market for investment firm Raymond James, strategist Tavis McCourt writes: “We are seeing a substantial rally in growth broadly in the last two weeks, and it is still unclear if this is
One key to market success is learning to recognize trends, overall directions that stocks are taking, and then riding those trends towards profitable returns. Sometimes, that task is easy; for instance, the five years from 2017 through the end of 2021 saw a prolonged run on generally increasing values. Sometimes, it’s more difficult; take a look at the charts for 2022 year-to-date and you’ll quickly see that there is no long-term direction of movement here. CNBC's Jim Cramer, however, believes t
Despite being one of the most recognizable wireless carriers in the U.S., AT&T stock has had a rough year. But it does have some perks.
Investors in Nio (NYSE: NIO) have waited for a day like this for a long time now. On April 1, Nio said it delivered a record number of electric vehicles (EVs), totaling 25,768 units, in the quarter ending March. Although that's barely 3% higher compared to the last quarter, expectations were even more muted given the severe supply challenges facing automakers like Nio.
The Chapter 11 petition was filed in response to an upcoming debt repayment obligation, Ruby said in a March 31 statement.
Vertex is one step closer to getting its new pain pill approved, which could substitute for opioids that are highly addictive.
In this article, we discuss the 10 stocks to buy and hold for over 5 years according to Bill Gates. If you want to read about some more stocks in the portfolio of Bill Gates, go directly to Bill Gates Portfolio: 5 Stocks to Buy and Hold for Over 5 Years. Bill Gates stepped down […]
Electric vehicles (EVs) are clearly the next big thing in the automotive industry, and they are supported by both social and political pressures toward ‘green’ technologies. For drivers, they offer a wide range of advantages over gasoline-powered cars: improvements in performance, fewer moving parts to wear out, quieter operations, easier integration into wireless networks. There are drawbacks, too. For now, EV battery range can match gasoline engines – but only at a higher cost for an already e
An investment in Nikola is a long-term journey, and there will be days of profit-taking along the way.
Every investor in Micron Technology, Inc. ( NASDAQ:MU ) should be aware of the most powerful shareholder groups...
ClearBridge Investments, an investment management firm, published its “Global Infrastructure Value Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. On an absolute basis, the Strategy delivered gains across six of the nine sectors in which it was invested (out of 11 total) in the fourth quarter, with the […]
Is Amazon stock a buy now that it announced a 20-for-1 stock split, its first in more than 20 years, along with a $10 billion stock buyback plan?
The analysts might have been a bit too bullish on UiPath Inc. ( NYSE:PATH ), given that the company fell short of...